



RECEIVED

FEB 06 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1800/2900

In re Patent Application of HANNA et al.

Group Art Unit: 1644

Application Serial No. 09/772,938

Examiner: Phillip Gambel

Filed: January 31, 2001

#9/A
gnd
2/5/03

Title: TREATMENT OF CELL MALIGNANCIES USING COMBINATION OF
B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY...

* * * * *

RECEIVED

JAN 06 2003

AMENDMENT AND REPLY

TECH CENTER 1600/2900

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Office Action dated July 2, 2002, please enter and consider the following amendments and remarks.

IN THE SPECIFICATION:

The specification is amended as described below, to correct minor informalities:

1. The paragraph beginning on page 1, line 24, is replaced with the following paragraph, in which "Rixtimab" is replaced with "Rituximab," and "C2B" is replaced with "C2B8, and "No's" is replaced with "Nos.":

a1 -- In fact, a chimeric anti-CD20 antibody, RITUXAN® (also known as Rituximab, MabThera®, IDEC-C2B8, and C2B8) is the first FDA approved monoclonal antibody for treatment of cancer (non-Hodgkin's lymphoma) and was developed by IDEC Pharmaceuticals Corporation (see US Patent Nos. 5,843,439; 5,776,456; and 5,736,137). --

2. The paragraph beginning on page 14, line 1, is replaced with the following paragraph, in which "<<1311" is replaced with "'¹³¹I ":

01/03/2003 SDXED051 00000108 033975 09722938

01 FC:1202 18.00 CH
02 FC:1253 930.00 CH